Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. The Danish drugmaker is paying ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ... and anti-amyloid therapy PRX004 in phase 2 for rare heart disease ATTR cardiomyopathy. ...

Novo Nordisk’sNOVO.B-2.58 % decrease; red down pointing triangle once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14% ...

Novo’s post-hoc data drop, which was published in the Lancet Friday, looked at heart failure outcomes in a total of 3,743 patients with a history of HFpEF across two semaglutide doses—2.4 mg ...

Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. Skip to main content ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney ...